KROS – keros therapeutics, inc. - common stock (US:NASDAQ)
Stock Stats
News
Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences
Keros Therapeutics (NASDAQ:KROS) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.
Zacks.com featured highlights include AES, BorgWarner, Enersys, PG&E and Keros Therapeutics [Yahoo! Finance]
KROS or ARGX: Which Is the Better Value Stock Right Now? [Yahoo! Finance]
Keros Therapeutics (NASDAQ:KROS) was upgraded by analysts at TD Cowen to a "hold" rating.
Form 4 Keros Therapeutics, Inc. For: Feb 18 Filed by: Lerner Lorena Raquel
Form 4 Keros Therapeutics, Inc. For: Feb 18 Filed by: Cho Esther
Form 4 Keros Therapeutics, Inc. For: Feb 19 Filed by: Seehra Jasbir
Form 4 Keros Therapeutics, Inc. For: Feb 18 Filed by: Regnante Keith
Form 8-K Keros Therapeutics, Inc. For: Feb 18
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.